409 related articles for article (PubMed ID: 16363884)
21. Danazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia.
Podhorecka M; Macheta A; Chocholska S; Bojarska-Junak A; Szymczyk A; Goracy A; Dmoszynska A; Hus M
Ann Hematol; 2016 Feb; 95(3):425-35. PubMed ID: 26692089
[TBL] [Abstract][Full Text] [Related]
22. Novel treatment strategies in chronic lymphocytic leukemia.
Weiss MA
Curr Oncol Rep; 2001 May; 3(3):217-22. PubMed ID: 11296131
[TBL] [Abstract][Full Text] [Related]
23. Treatment of chronic lymphocytic leukaemia. French Co-operative Group on CLL.
Binet JL
Baillieres Clin Haematol; 1993 Dec; 6(4):867-78. PubMed ID: 8038494
[TBL] [Abstract][Full Text] [Related]
24. What is the optimal initial treatment for chronic lymphocytic leukemia?
Lin TS
Oncology (Williston Park); 2007 Dec; 21(14):1641-9; discussion 1649-54, 1659, 1662. PubMed ID: 18247015
[TBL] [Abstract][Full Text] [Related]
25. Purine analogue-based chemotherapy regimens for patients with previously untreated B-chronic lymphocytic leukemia.
Kay NE
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S50-4. PubMed ID: 16549115
[TBL] [Abstract][Full Text] [Related]
26. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells.
Bouzar AB; Boxus M; Defoiche J; Berchem G; Macallan D; Pettengell R; Willis F; Burny A; Lagneaux L; Bron D; Chatelain B; Chatelain C; Willems L
Br J Haematol; 2009 Jan; 144(1):41-52. PubMed ID: 19006566
[TBL] [Abstract][Full Text] [Related]
27. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells.
Smolewski P; Szmigielska-Kaplon A; Cebula B; Jamroziak K; Rogalinska M; Kilianska Z; Robak T
Leuk Lymphoma; 2005 Jan; 46(1):87-100. PubMed ID: 15621786
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal antibodies in the treatment of chronic lymphocytic leukemia.
Liu NS; O'Brien S
Med Oncol; 2004; 21(4):297-304. PubMed ID: 15579912
[TBL] [Abstract][Full Text] [Related]
29. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.
Robak T; Lech-Maranda E; Korycka A; Robak E
Curr Med Chem; 2006; 13(26):3165-89. PubMed ID: 17168705
[TBL] [Abstract][Full Text] [Related]
30. New prospects in the treatment of indolent lymphomas with purine analogues.
Cheson BD
Cancer J Sci Am; 1998 Jul; 4 Suppl 2():S27-36. PubMed ID: 9672772
[TBL] [Abstract][Full Text] [Related]
31. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
O'Brien S; Kantarjian H; Estey E; Koller C; Robertson B; Beran M; Andreeff M; Pierce S; Keating M
N Engl J Med; 1994 Feb; 330(5):319-22. PubMed ID: 7904047
[TBL] [Abstract][Full Text] [Related]
32. Achieving optimal outcomes in chronic lymphocytic leukaemia.
Hamblin TJ
Drugs; 2001; 61(5):593-611. PubMed ID: 11368285
[TBL] [Abstract][Full Text] [Related]
33. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.
Weiss MA; Maslak PG; Jurcic JG; Scheinberg DA; Aliff TB; Lamanna N; Frankel SR; Kossman SE; Horgan D
J Clin Oncol; 2003 Apr; 21(7):1278-84. PubMed ID: 12663715
[TBL] [Abstract][Full Text] [Related]
34. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients.
Eketorp Sylvan S; Lundin J; Ipek M; Palma M; Karlsson C; Hansson L
Ann Hematol; 2014 Oct; 93(10):1725-33. PubMed ID: 24844780
[TBL] [Abstract][Full Text] [Related]
35. Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488.
Oken MM; Lee S; Kay NE; Knospe W; Cassileth PA
Leuk Lymphoma; 2004 Jan; 45(1):79-84. PubMed ID: 15061201
[TBL] [Abstract][Full Text] [Related]
36. [Experience with fludarabine treatment and review of the literature].
Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
[TBL] [Abstract][Full Text] [Related]
37. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
38. Pentostatin in chronic lymphocytic leukemia.
Sauter C; Lamanna N; Weiss MA
Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1217-22. PubMed ID: 18721115
[TBL] [Abstract][Full Text] [Related]
39. Chronic lymphocytic leukemia treatment.
Dighiero G
Hematol Cell Ther; 1997 Nov; 39 Suppl 1():S31-40. PubMed ID: 9471059
[TBL] [Abstract][Full Text] [Related]
40. Advancing therapy for chronic lymphocytic leukemia--the role of rituximab.
Hillmen P
Semin Oncol; 2004 Feb; 31(1 Suppl 2):22-6. PubMed ID: 15042531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]